The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia

por García-Tuñón, Ignacio, Hernández-Sánchez, María, Ordoñez, José Luis, Alonso-Pérez, Veronica, Álamo-Quijada, Miguel, Benito, Rocio, Guerrero, Carmen, Hernández-Rivas, Jesús María, Sánchez-Martín, Manuel
Publicado 2017